Aflac (AFL) Q4: Product Launches and Distribution Expansion Drive Mixed Results

Aflac (NYSE:AFL) reported Q4 CY2025 revenue of $4.28B, flat year-over-year, and non-GAAP earnings of $1.57 per share, 7.3% below consensus. Despite the miss, shares rose to $117.79 from $113.62. In Japan, sales advanced 15.7% YoY driven by new cancer and medical products; in the U.S., group business and disciplined underwriting supported premium growth. Management attributed resilience to strong persistency, expanded distribution, and reinsurance/paid-up impacts. CEO Daniel Amos and CFO Max Broden highlighted ongoing automation and technology investments to improve efficiency and scale new lines. Looking ahead, key watchpoints include traction of recent launches, expense and net earned premium trends, and the pace of digital distribution expansion. AFL faces margin pressure from product mix shifts and higher expenses, balanced by persistency gains and disciplined underwriting.